Tocqueville Asset Management L.P. Bluebird Bio, Inc. Transaction History

Tocqueville Asset Management L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 31, 2019	SELL	$59.47 - $93.1 $287,834 - $450,604	-4,840 Closed	0 $0
Q2 2019 Jul 31, 2019	SELL	$75.84 - $105.21 $341,280 - $473,445	-4,500 Reduced 48.18%	4,840 $616,000
Q1 2019 Apr 30, 2019	BUY	$64.44 - $104.11 $311,889 - $503,892	4,840 Added 107.56%	9,340 $1.47 Million
Q4 2018 Feb 08, 2019	SELL	$59.1 - $93.26 $2.97 Million - $4.69 Million	-50,260 Reduced 91.78%	4,500 $446,000
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $125,736 - $166,248	1,415 Added 2.65%	54,760 $8 Million
Q2 2018 Aug 13, 2018	BUY	$99.64 - $127.59 $2.73 Million - $3.49 Million	27,380 Added 105.45%	53,345 $8.37 Million
Q1 2018 May 14, 2018	SELL	$105.8 - $150.94 $306,820 - $437,726	-2,900 Reduced 10.05%	25,965 $4.43 Million
Q4 2017 Feb 13, 2018	SELL	$81.25 - $130.7 $2.18 Million - $3.51 Million	-26,825 Reduced 48.17%	28,865 $5.14 Million
Q3 2017 Oct 30, 2017	BUY	$57.74 - $91.42 $3.22 Million - $5.09 Million	55,690	55,690 $7.65 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.